Literature DB >> 33525741

DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment.

Takayuki Saitoh1, Tsukasa Oda2.   

Abstract

Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by genomic instability. MM cells present various forms of genetic instability, including chromosomal instability, microsatellite instability, and base-pair alterations, as well as changes in chromosome number. The tumor microenvironment and an abnormal DNA repair function affect genetic instability in this disease. In addition, states of the tumor microenvironment itself, such as inflammation and hypoxia, influence the DNA damage response, which includes DNA repair mechanisms, cell cycle checkpoints, and apoptotic pathways. Unrepaired DNA damage in tumor cells has been shown to exacerbate genomic instability and aberrant features that enable MM progression and drug resistance. This review provides an overview of the DNA repair pathways, with a special focus on their function in MM, and discusses the role of the tumor microenvironment in governing DNA repair mechanisms.

Entities:  

Keywords:  DNA damage response; DNA repair; base excision repair; genomic instability; homologous recombination; multiple myeloma

Year:  2021        PMID: 33525741      PMCID: PMC7865954          DOI: 10.3390/cancers13030504

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  188 in total

1.  Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli.

Authors:  Zhao-Hui Wu; Yuling Shi; Randal S Tibbetts; Shigeki Miyamoto
Journal:  Science       Date:  2006-02-24       Impact factor: 47.728

2.  Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma.

Authors:  Elisa Taiana; Vanessa Favasuli; Domenica Ronchetti; Katia Todoerti; Francesca Pelizzoni; Martina Manzoni; Marzia Barbieri; Sonia Fabris; Ilaria Silvestris; Maria Eugenia Gallo Cantafio; Natalia Platonova; Valeria Zuccalà; Lorenza Maltese; Debora Soncini; Samantha Ruberti; Michele Cea; Raffaella Chiaramonte; Nicola Amodio; Pierfrancesco Tassone; Luca Agnelli; Antonino Neri
Journal:  Leukemia       Date:  2019-08-19       Impact factor: 11.528

3.  Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.

Authors:  Rakesh Popat; Lenushka Maharaj; Heather Oakervee; Jamie Cavenagh; Simon Joel
Journal:  Br J Haematol       Date:  2012-10-18       Impact factor: 6.998

4.  Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination.

Authors:  P L Roddam; S Rollinson; M O'Driscoll; P A Jeggo; A Jack; G J Morgan
Journal:  J Med Genet       Date:  2002-12       Impact factor: 6.318

5.  The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.

Authors:  Sabine Kayser; Konstanze Döhner; Jürgen Krauter; Claus-Henning Köhne; Heinz A Horst; Gerhard Held; Marie von Lilienfeld-Toal; Sibylla Wilhelm; Andrea Kündgen; Katharina Götze; Mathias Rummel; David Nachbaur; Brigitte Schlegelberger; Gudrun Göhring; Daniela Späth; Carina Morlok; Manuela Zucknick; Arnold Ganser; Hartmut Döhner; Richard F Schlenk
Journal:  Blood       Date:  2010-12-02       Impact factor: 22.113

6.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

7.  The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.

Authors:  Heather J Landau; Samuel C McNeely; Jayasree S Nair; Raymond L Comenzo; Takashi Asai; Hillel Friedman; Suresh C Jhanwar; Stephen D Nimer; Gary K Schwartz
Journal:  Mol Cancer Ther       Date:  2012-05-31       Impact factor: 6.261

Review 8.  Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.

Authors:  Naveen Singh; S Louise Pay; Snehal B Bhandare; Udhaya Arimpur; Edward A Motea
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

Review 9.  Reactive oxygen species (ROS) as pleiotropic physiological signalling agents.

Authors:  Helmut Sies; Dean P Jones
Journal:  Nat Rev Mol Cell Biol       Date:  2020-03-30       Impact factor: 113.915

Review 10.  Reactive Oxygen Species: A Key Constituent in Cancer Survival.

Authors:  Seema Kumari; Anil Kumar Badana; Murali Mohan G; Shailender G; RamaRao Malla
Journal:  Biomark Insights       Date:  2018-02-06
View more
  3 in total

Review 1.  Genomic Instability in Multiple Myeloma: A "Non-Coding RNA" Perspective.

Authors:  Elisa Taiana; Maria Eugenia Gallo Cantafio; Vanessa Katia Favasuli; Cecilia Bandini; Giuseppe Viglietto; Roberto Piva; Antonino Neri; Nicola Amodio
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

2.  THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors.

Authors:  Pavithra Shyamsunder; Shree Pooja Sridharan; Vikas Madan; Pushkar Dakle; Cao Zeya; Deepika Kanojia; Wee-Joo Chng; S Tiong Ong; H Phillip Koeffler
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

3.  Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways.

Authors:  Kubra Karagoz; Matthew Stokes; María Ortiz-Estévez; Fadi Towfic; Erin Flynt; Sarah Gooding; William Pierceall; Anjan Thakurta
Journal:  Front Genet       Date:  2022-02-09       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.